Highlights GENFIT

Equities

GNFT

FR0004163111

Market Closed - Euronext Paris Other stock markets 11:39:05 2024-05-09 am EDT			After market 03:59:57 pm
3.37 ^EUR	0.00%		3.373	+0.09%

May. 08	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	MT
May. 01	European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	May. 08	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	May. 01	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
Genfit: net loss widens in 2023	Apr. 05	CF
Genfit S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
Genfit: 41% sales growth in 2023	Mar. 01	CF
GENFIT Announces Updates Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis	Dec. 08	CI
Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC	Dec. 07	CI
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+ as a Screening Tool for the Enrollment of Patients in Mash Clinical Trials	Dec. 06	CI
Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial	Nov. 13	CI
GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology	23-09-26	CI
Genfit S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications	23-08-10	CI
Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease	23-06-30	CI
GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program	23-05-09	CI
Genfit S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GENFIT

Equities

GNFT

FR0004163111

Highlights

Filters